
Immunoglobulins Market Report 2026
Global Outlook – By Product (IGG, IGA, IGM, IGE, IGD), By Mode Of Delivery (Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications) – Market Size, Trends, Strategies, and Forecast to 2035
Immunoglobulins Market Overview
• Immunoglobulins market size has reached to $20.32 billion in 2025 • Expected to grow to $34.52 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Increasing Healthcare Expenditures Are Anticipated To Boost The Immunoglobulins Market • Market Trend: Innovative Product Launches Drive Growth in the U.S. Immunoglobulins Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Immunoglobulins Market?
Immunoglobins refer to glycoproteins, often known as antibodies, that are created by plasma cells (white blood cells). They play a crucial role in the immune response by selectively identifying and attaching to specific antigens, such as viruses or bacteria, and assisting in their eradication. The main types of products in immunoglobulins are IGG, IGA, IGM, IGE, and IGD. Immunoglobulin G (IGG) is the primary stimulator of humoral immunity in extracellular fluids such as blood, lymph, and saliva. The immunoglobulins are delivered using the intravenous mode of delivery, subcutaneous mode of delivery and are used in hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), others.
What Is The Immunoglobulins Market Size and Share 2026?
The immunoglobulins market size has grown rapidly in recent years. It will grow from $20.32 billion in 2025 to $22.52 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to growing prevalence of immunodeficiency diseases, increasing autoimmune disorder cases, rise in hospital infrastructure, technological advancements in plasma fractionation, expanding awareness about antibody therapies.What Is The Immunoglobulins Market Growth Forecast?
The immunoglobulins market size is expected to see rapid growth in the next few years. It will grow to $34.52 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in personalized medicine, development of novel monoclonal antibodies, increased home-based subcutaneous therapies, expansion of biotechnology and research centers, growing government support for immunotherapy programs. Major trends in the forecast period include personalized immunoglobulin therapy, increasing adoption of subcutaneous delivery methods, rising demand for ivig in autoimmune disorders, expansion of rare immunodeficiency treatments, growth in monoclonal antibody research.Global Immunoglobulins Market Segmentation
1) By Product: IGG, IGA, IGM, IGE, IGD 2) By Mode Of Delivery: Intravenous Mode Of Delivery, Subcutaneous Mode Of Delivery 3) By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications Subsegments: 1) By IGG (Immunoglobulin G): IVIG (Intravenous Immunoglobulin), SCIG (Subcutaneous Immunoglobulin) 2) By IGA (Immunoglobulin A): Monoclonal IGA, Polyvalent IGA 3) By IGM (Immunoglobulin M): Monoclonal IGM, Polyvalent IGM 4) By IGE (Immunoglobulin E): Allergen-Specific IGE, Monoclonal IGE 5) By IGD (Immunoglobulin D): Research-Use IGD, Monoclonal IGDWhat Is The Driver Of The Immunoglobulins Market?
The rising healthcare expenditure is expected to propel the growth of the hyperphosphatemia treatment market going forward. Hyperphosphatemia treatment involves therapies and medications aimed at reducing elevated phosphate levels in the blood, which commonly occur in patients with chronic kidney disease and other related conditions. Increased healthcare spending allows for broader access to such treatments, supports research and development of advanced therapies, and improves patient management strategies. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based Institute for Health Information, in 2023, total health spending in Canada is projected to reach $344 billion, equating to $8,740 per person. This marks a 2.8% increase compared to 2022, which saw only a 1.5% growth in health spending in 2022, indicating a notable rebound in healthcare investment. Therefore, the increasing healthcare expenditure is driving the growth of the hyperphosphatemia treatment market.Key Players In The Global Immunoglobulins Market
Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare LimitedGlobal Immunoglobulins Market Trends and Insights
Major companies operating in the immunoglobulins market are developing innovative products such as intravenous immunoglobulins to meet larger customer bases, more sales, and increase revenue. For instance, in September 2024, GC Biopharma, a South Korean-based biotechnology company, launched ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market, targeting the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. now available to patients through specialty pharmacies. The launch is significant as the U.S. represents the largest immunoglobulin market globally, valued at approximately $11.6 billion. GC Biopharma aims to achieve $50 million in sales for ALYGLO in its first year, with plans to increase this figure to $300 million by 2028. This ambitious growth strategy involves partnerships with major U.S. pharmacy benefit managers and specialty pharmacies, which are crucial for distributing immunoglobulin products effectively.What Are Latest Mergers And Acquisitions In The Immunoglobulins Market?
In July 2024, Biogen Inc., a US-based biotechnology company, acquired Human Immunology Biosciences (HI-Bio) for an undisclosed amount. Through this acquisition, Biogen gains HI-Bio’s lead asset, felzartamab, a fully human anti-CD38 monoclonal antibody being developed for conditions such as IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and antibody-mediated rejection (AMR) in transplant patients, thereby reinforcing Biogen’s immunology and immunoglobulin-related disease pipeline. Human Immunology Biosciences is a US-based developer of fully human monoclonal antibodies.Regional Insights
North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Immunoglobulins Market?
The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Immunoglobulins Market Report 2026?
The immunoglobulins market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Immunoglobulins Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $22.52 billion |
| Revenue Forecast In 2035 | $34.52 billion |
| Growth Rate | CAGR of 10.8% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Product, Mode Of Delivery, Application |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
